enableCV

enableCV specializes in perfusion devices that ensure continuous blood flow during cardiac surgery procedures, spanning from traditional open-heart surgeries to cutting-edge minimally invasive approaches. With strong surgeon preference for its products, enableCV serves more than 600 medical institutions across 30+ countries through its comprehensive portfolio of cardiac surgery solutions. The company maintains a robust innovation pipeline developed in collaboration with a medical advisory board of preeminent cardiothoracic surgeons to continuously improve the experience and outcomes of surgeons and their patients. Building on its strong heritage with Edwards LifeSciences, enableCV partnered with Water Street in 2025 to accelerate product development, expand its global footprint, and advance breakthrough innovations in cardiac surgery.